PH26994A - Antiviral nucleosides - Google Patents
Antiviral nucleosides Download PDFInfo
- Publication number
- PH26994A PH26994A PH35500A PH35500A PH26994A PH 26994 A PH26994 A PH 26994A PH 35500 A PH35500 A PH 35500A PH 35500 A PH35500 A PH 35500A PH 26994 A PH26994 A PH 26994A
- Authority
- PH
- Philippines
- Prior art keywords
- bad original
- compound
- azido
- deoxythymidine
- tha
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title description 5
- 239000002777 nucleoside Substances 0.000 title description 3
- 125000003835 nucleoside group Chemical group 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims description 33
- 238000009472 formulation Methods 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 31
- 208000015181 infectious disease Diseases 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 24
- 239000004480 active ingredient Substances 0.000 description 17
- 239000000460 chlorine Substances 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 208000030507 AIDS Diseases 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000001226 triphosphate Substances 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 5
- 239000003610 charcoal Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- -1 s Species 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- 235000011178 triphosphate Nutrition 0.000 description 5
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 229940069328 povidone Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 150000004712 monophosphates Chemical class 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 101100004031 Mus musculus Aven gene Proteins 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 240000004713 Pisum sativum Species 0.000 description 2
- 235000010582 Pisum sativum Nutrition 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SBSGEUBHXXHNBQ-RWRJDSDZSA-N (2s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-2-aminopropanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N SBSGEUBHXXHNBQ-RWRJDSDZSA-N 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- QWZNMUPRNVZTEK-XVKPBYJWSA-N 1-[(2R,5S)-2-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(N=[N+]=[N-])O[C@H](CO)CC1 QWZNMUPRNVZTEK-XVKPBYJWSA-N 0.000 description 1
- WFZVLYHEWQAQMG-RNSXUZJQSA-N 1-[(2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-methylsulfonyloxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(S(C)(=O)=O)O[C@H](CO)[C@@H](O)C1 WFZVLYHEWQAQMG-RNSXUZJQSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OKQHSIGMOWQUIK-UHFFFAOYSA-N 2-[(2-aminopurin-9-yl)methoxy]ethanol Chemical compound NC1=NC=C2N=CN(COCCO)C2=N1 OKQHSIGMOWQUIK-UHFFFAOYSA-N 0.000 description 1
- VEUMANXWQDHAJV-UHFFFAOYSA-N 2-[2-[(2-hydroxyphenyl)methylideneamino]ethyliminomethyl]phenol Chemical compound OC1=CC=CC=C1C=NCCN=CC1=CC=CC=C1O VEUMANXWQDHAJV-UHFFFAOYSA-N 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 206010001513 AIDS related complex Diseases 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- FDQGNLOWMMVRQL-UHFFFAOYSA-N Allobarbital Chemical compound C=CCC1(CC=C)C(=O)NC(=O)NC1=O FDQGNLOWMMVRQL-UHFFFAOYSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101100309713 Arabidopsis thaliana SD129 gene Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 101100272279 Beauveria bassiana Beas gene Proteins 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 101100173542 Caenorhabditis elegans fer-1 gene Proteins 0.000 description 1
- 239000012695 Ce precursor Substances 0.000 description 1
- 240000008365 Celosia argentea Species 0.000 description 1
- 235000000722 Celosia argentea Nutrition 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 241000272470 Circus Species 0.000 description 1
- 235000011777 Corchorus aestuans Nutrition 0.000 description 1
- 240000004792 Corchorus capsularis Species 0.000 description 1
- 235000010862 Corchorus capsularis Nutrition 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 235000008375 Decussocarpus nagi Nutrition 0.000 description 1
- 244000309456 Decussocarpus nagi Species 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 235000016936 Dendrocalamus strictus Nutrition 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000238558 Eucarida Species 0.000 description 1
- 102000004678 Exoribonucleases Human genes 0.000 description 1
- 108010002700 Exoribonucleases Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000772194 Homo sapiens Transthyretin Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 241001175904 Labeo bata Species 0.000 description 1
- 241000191405 Lewia Species 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000357437 Mola Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 description 1
- 102000013901 Nucleoside diphosphate kinase Human genes 0.000 description 1
- 102100032341 PCNA-interacting partner Human genes 0.000 description 1
- 101710196737 PCNA-interacting partner Proteins 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000002390 Pandanus odoratissimus Species 0.000 description 1
- 235000005311 Pandanus odoratissimus Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 102100024078 Plasma serine protease inhibitor Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100039028 Protein SPO16 homolog Human genes 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 101150108548 SPO16 gene Proteins 0.000 description 1
- 235000014328 Schoenoplectus acutus var occidentalis Nutrition 0.000 description 1
- 235000014326 Scirpus californicus Nutrition 0.000 description 1
- 244000078283 Scirpus lacustris Species 0.000 description 1
- 235000017913 Scirpus lacustris Nutrition 0.000 description 1
- 241001067759 Senta Species 0.000 description 1
- JXVIIQLNUPXOII-UHFFFAOYSA-N Siduron Chemical compound CC1CCCCC1NC(=O)NC1=CC=CC=C1 JXVIIQLNUPXOII-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 241001130469 Tila Species 0.000 description 1
- 241000613130 Tima Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100029290 Transthyretin Human genes 0.000 description 1
- 101710100179 UMP-CMP kinase Proteins 0.000 description 1
- 101710119674 UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940060515 aleve Drugs 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 229940030850 avar Drugs 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SMDHCQAYESWHAE-UHFFFAOYSA-N benfluralin Chemical compound CCCCN(CC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O SMDHCQAYESWHAE-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- MXKOAPUYOVRCDD-UYVBYVPASA-N diazonio-[(2s,3s,5r)-2-[hydroxy(methylsulfonyl)methyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]azanide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](C(O)S(C)(=O)=O)[C@@H]([N-][N+]#N)C1 MXKOAPUYOVRCDD-UYVBYVPASA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- UJHBVMHOBZBWMX-UHFFFAOYSA-N ferrostatin-1 Chemical compound NC1=CC(C(=O)OCC)=CC=C1NC1CCCCC1 UJHBVMHOBZBWMX-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229910001418 francium ion Inorganic materials 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- IVSXFFJGASXYCL-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=NC=N[C]21 IVSXFFJGASXYCL-UHFFFAOYSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- REEZZSHJLXOIHL-UHFFFAOYSA-N octanoyl chloride Chemical compound CCCCCCCC(Cl)=O REEZZSHJLXOIHL-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003415 peat Substances 0.000 description 1
- 244000144985 peep Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000013146 percutaneous coronary intervention Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 description 1
- AXVOAMVQOCBPQT-UHFFFAOYSA-N triphos Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 AXVOAMVQOCBPQT-UHFFFAOYSA-N 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
A
Antiviral Nucleosides
This application is a divisional of patent application Serial No. 33532 filed March 14, 1986, '
The present invention relates to 3-azido-3"- deoxythymidine, its pharmaceutically arceptahln derivatives and their use in the treatmant or prophy- laxis of human ratroviral infections. ‘ Retroviruses form a sub-group of RNA viruses whieh, in order to replicate, must first 'reverse 10 . transcribe’ the RNA of their genome ioto DNA (transcription' conventionally describes the synthe: sis of RNA from DNA). Once in the form of DNA, the viral genome is incorporated into the host cell genome, allowing it to take full advantage of the host - Is cells transcription/tranglation machinery for the purposes of replication. Once incorporated, the viral
DNA is virtually indistinguishahble from the host's
DNA and, in this state, the virus may persist for as long as the cell lives. As it is virtvally invulne- rable to attack in this form, any treatment must be directed at another state of the life cycle and will, of necessity, have to be continued until all virus- carrying cells have died. . BAD ORIGINAL Yi el 4 ,
HTLV--1 and HTLV--IT are both rotroviruses and are known to be causative agents of leukaemia in man.
HTLV-~I infactions are especially widespread and are responsible for many deaths world-wide each year.
A species of retrnvirng has now been reproducibly isolated from patients with AIDS. While it has been extensively characterized, there is. ns yet, no agreed name for the virus, and it is currently known either as human T-cell lymphotropic virus 1173 (nT1¥ 111),
AlDS-associated retrovirus (ARV), or lymphadenopathy associated virus (LAV), It is anticipat d that the name to ba agresd on internationally is aquired immune defi- ciency virus (ALDV). This virus (refarred to herein ans
AIDV) has been shown preferentially to infect and des- troy T-cella bearing the okr" surface marker and is now generally accepted ns the antiologic agent of AIDS.
The patient progressively loses this set of I~cells, upsetting the overall balance of the immune system, re- ducing his ability to combat other infections, and pre- disposing him to opportunistic infections which frequent- ly prove fatal. Thus, the usual cause of death in AIDS victims is by opportunistic infection, such as pneumonia or vitally induced cancers, and not as a direct result of AIDV infection. - lb - [ .
BAD ORIGINAL 9
: 26d §
Recently, AlLUV has alro been rocovered from other tissue types, including B-cells expressing the 7 marker, macrophages and non-blood asanciated tinsue in the central nervous system (Ul). This latter infection has been discovered in patients expressing classical . AIDS symptoms and is associated with progressive demy- elination. ILwading to waating and such aymptoma as encephalopathy, progressive dysarthria, ataxia and disorientation.
There are at lemat fonr enlinical manifestations “of AIDV Infection. In the initinl ‘carrier! =tate, the only indication of infection is the preaence of anti-
AIDV antibodies in the blood-atream, It ia believed thant such 'carriers' are capable of passing on tha infection defo by blond tranafusion, sexual intercourse or used : syringe needlea, The carrier atate may often naver progress to ‘the second stage characterized by persistent generalised lymphndenopathy (POL). It in currently estimated that about 20% of I'GL patiants rrogress to a more advanced condition known as ‘IDS related complex’ (ARC). Physical aymptoms ansociated with ARC may include general mnlaise, increased temperature and chronie¢ infections. Thin condjtion veuglly propgrnsses to the final, fatal AID5 condition, when the patient completely loses ths ability to fight inféction. ) -5- BAD ORIGINAL 9
L
Co | | 6A
The existence of thess human retroviruses and others has only recently been recognised and, as tho dideases with which they are linked sre of a life- threatening nature, there exists an urgent naed to develop ways to combat these viruses.
Various drugs have now been proposed an ‘cures’ for AIDS. These include antimoniotungstate, suramin, ribavirin and $soprinoaine, which are either somewhat toxic or have ahown no matked anti-retroviral activity.
As the AIDV genome is incorporated into the host cell
DNA after infection and is virtually invulnerable to * attack in this atate, it will peraist as long as the host cell survives, causing new infection in the mean- time. Thus, any treatment of AIDS would have to be for an extended period, possibly life, requiring substances with an acceptable toxicity.
LL Ce Reporta have described thn testing of compounds. re against various retroviruses, for example, Friend lLeukaa- mia Virus (FLV), a murine retrovivuas. For instance
Krieg st al. (Fxp. Cell Res., 116 (1978) 21-29) found 3'epgzido-3'-deoxythymidine to be active ngainat FLV in in vitro experiments, and Ustertag et al. (Proc. Hat.
Acad. Sei. (1974) 71, 1980-85) atated that, oa the basis : of antiviral activity related to FLV and a lack of - 6 - : . BAD ORIGINAL 9 oo | 2aq ‘cellular toxicity, 3'—azida-3'-dacxythyniding "might favourably replace hromodeosyuridine for medical treatment of diseassg cauand hy INA viruses".
De Clera et al. (Biochem, Fharm, (1930) 272,, 1849- 1851) eatablishad, six vears latar, that 3°. deoxythymidine had no appreciable activity any viruses uged in thelr tests, including vaccinia,
HEVI and vericmlla zoster virns (VZV). Clinski et al. (J. Orn. Chem. (1973), 38, 4199-41305) discloacs certain derivatives of Jeuride-3' -Aanvythymidline (Infra) and thelr ability to hiock wamealian exori- bonuclease antivity. . - We have now discovered that 3'-arido-3'-deoxy- thymidine has a surprisingly potent activity against human retrovirnsms, «with a particularly high activity against AIDV as demonstrated by the a<parimental data veferred to helow. Such activity -anders the _ codpound useful in the theraphy of human retroviral "infections.
Thus, in a first aspect of the prceant invantion, there ig provided a compound of fornuls (1): . Lo oo TACINAL dP
Babs Or
0
A. OH
AN +
I Ae 0” >%
Ho LO - \__./ m, (1. e. A amido carat hem bd ban Coy 2 - vharmaoantine) ty acaba be Am fogb fae
Fhaoyaef for vies bp IP Fpsen meat ar prophylavin of hops ratyay ive Infect inne )
B the compo of terms re ard He pharmacentionl lv noosotabys ola vrata ag Ape herauf te, ve ferred te np tha Carnie according to the Invention ’ | Bel tvity of A -mnlde 3 cdaovethvind od tne @ aaninat hman yetrovieasen hop Boor artabl ished . bri way dean in v)trr SELEY Aviat Foy \ axpmple, infecting af the HR hvman
Iymphabtantold rell- line be ATHY |p nf foctively i prevented be corcebrations of A" nzide-as 16 deoxy Lhymldine ap low se 6.010 meg sm vp te 20 oo benes after infeat ion. AIDY infant icn o § HIT om .
BAD ORIGINAL J oo | 2qq( i himan lvymphoblaagtoid colle, PHA - emtimnlated ~ a white hlood nelle and eulinred periphsral blood Fymphonvien fe aloo prevent «rl at eimilarly low concaptrationge In addition, 100. 6 day challange axpaviments nping up bo BOA ATDY virions par cal) and alonad T4, fetannnp : apecifi,, T-helper Jwvemphocvtas, slowed no decreass In calle trested with 2 -asido-3 - deoxythvmidine, while untreated aells had 19 decreapged h-fold. COytopathie effacte were alec completely blaockad in the seme amll-1ine trannformad by HTLY-T and puper-infanted with
ATDV.,
Other studias uring purified AINY ravarage 16 transcriptase have shaun that the activity of this enavme ie blocked by the triphosphate of dA ~anido-3 -deoxythvmidine by a competitive inhibition mechanlem.
Fhaea TT olinical trisle have ahoun that 3°.
A" azido~-3 ~daonxythymidine is aapahle of orogeing " . the blood/brain harrier in clinteally effective quanntitiece. This property ie both
BAD ORIGINAL 9 a I) 53 ot ‘ “py ; Vo . : ii sy io . E s ‘ MN £2 i: BE a IB
NE angst and valuable for the bEreatwmeal and 0 3 KY. - . . . (I
Fi prophylaxis of CHS infections caused by human ‘4 _. rebroviiinusss. iH yr i i 3 kl:
HE il
A hs The ability of 3 -asido-3 -deoxvthvmidine Bd if 8
SS: . Ln . IR ‘ b to wodify the course of retrovirus induced fH ge i J + 3 malignancy has bean demonstrated in a monse 4 a ae
Ly modal, whareby administration of 3 -azido-3 #
REY] - Fhe
Lig deodyvthymidine prevented splenomegaly caused by IE
SR LE
4d : intravenously administered HKauscher Murine iB a. if » ; i ; i 13 Leukaemia Yirue, the marine eguivalent of HTLV - iE
I ” | I) yor : aq A , hy I. lin Turthor experiments, 37 asido-37- | § - .
Y % decsvthyvmlidine has been shown to inhibit the ja a: mn vitro replication of HTLV-T at ooncentrations Do 4 3 as low as 9.8 meg ml. Ve bg : i : i ne =. 15 Thus, in a further, preferred aspect of the Eb bh , . . it! ; i present. invention, there is provided the use of 2 x a componind according to the Invention in the & 3 manufacture of a medicament for the treatment ? : or prophylaxis of human refrovirng infections. | £ ® 2a The praesent invention farther provides a FB
BR. ¥ ; 4 method for the treatment ov prophyviasis of AIRS ii x 4 p 4 ji! 1 ad 3 ‘WR 5 4
B! FS
M 2 y ts i 1 - 1 i i]
A i 4 nA i, I a , AL id » BAD ORIGINAL oy i “3 a.
Eda: St ER ta ERI Copmd aA ee Wh BRE Lo. Cle . . o
Pe ene. ER ET TERMS RTT J pe SE
HAL ce A we To : gt . SP NI Bik
Are TY ie : N Cy
ER in » human eubjant whinh cowprirer i - | aduwinietering te the sald human enbject an : affective amount of a cowpound according to the
IEEE invention. b Tha present Invention also includes a . method for the treatment or propheinxie of : infections oauged hy retroviruses ‘nv a human oe Co aubjgzct, which comprises adninisterivg to the : N, a
Co sald human aAubject an effectyve antlvira) oo 109 apount of a nompound according to the ay invention. : i . . . A .
A ~~ The praement inventlon further provides a , compound acaording to the invention for vee in : oH ee mmm phe treatment of prophylaxis of AIDS cr oa virus
Sh : ya : : 18 infection ans identified above. er . 0 Examples of human ratroviruy infections :
Ty _ ®hieh may be treatad or prevented Jon accordsnce
Ch with: the pressnnt fuventlon fncinde T-cell
To lymphotrople retrovirvess (HTLV). especially
Ce 20 HTLV-I, HTLV-11 and ALDV (HTLV-II1). . 1 - | - BAD ORIGINAL 37
. i - wee HERE SE ek + gd i;
Si | . - Olinieal conditions that may be treated or ’ prevented in accordance with the tnvention oe | include AIDS, AIDS-related complex and HTLV-T positive leuksemia and lymphoma. Suitable . Co 6 patients for treatment alec include thore - having antibodies to AIDV, AIDV CNS infections,
CL - PAL and ARC. " By "a pharmaceutically acceptable i - derivative” Js meant any charmaceutically i. 10 acceptable galt, ester, or salt of such ester, ’ z : or any othar compound which, upon oo | administration to a human subject. is capable oo of providing (directly or indirectly) a- - azido-3’ -deoxythymidine or an anti-retrovirally 16 avtive metabolite or residus thereof. An
Sn v example of a non-eater compound Is the
MA : derivative wherein the B-C- and 2-C-atoms nt are linked by an oxygen atom to form an anhydre
Ea - group. { : .
B ; 20 + Preferred esters of the compound of formula Ce | (1 include carboxylic acid estara in which the .
Cd So no - 12 - : ; oo BAD ORIGINAL 9 = ne oo me bh eh Coa . CL . . o
Wa orn: CE TT wg ask
LT — nolety of the ator grouping ia aalected fram strataht or branched chain alkyl, ] } Alkoryalkyl (e.g. wathaxvymethyl), aralkyl (ag. oo benny 1), arvicwyrslkel (eg. phonavymathvl), oo Bb aryl ta.g. vhenvl «ptionsliy substituted by oo halogen, Cy.q »leyl or Cy, alkoxy); sulphonate niutore Anh Be Alka d= or ) aralky lan) phony! Cie og wathaneauliphions yy ad - . nono df, or tri-phogphsta esters, With - 1a regs to tha shove degsovibed cplors, unlsen abherulne ppenitied apy wlhvl peiablos present in swh enters sbeontngeonsly contain {Lo 18 : carbon atom, poartionlesrly | toe 4 earbon sloms. ] Any. muy! molaty preagent din gnch enters 3 : 15 adysntageoue iy Acmpriean nv vhenyl gronp, Any oo referen-e te any of the hove cowmpoonde salen oe oo ineludes & cafacepers tas pharmaceutically a. at nocsptuhle salt Lhareaf.
Co Rxperimente have phown that 37 -naldo-3°- )
Ay 20 deoxythymidine ie cemyartad, ‘ig vitro, by the : action of asl line earymes Into Lhe br- E
Fr : manopharphato The mormphosphste 16 then
Be | R further phosphorylated by other enaymes to form : \ : i . ) EB \
So : - 13 , - : “ Co co BAD ORIGINAL 9 :
Wer CWT ga
Vo pith Ce Eo. Sagrp J 7 : HEE Ch | : we : awl
Ea : LY
CE : ‘
Lh : Lo . - eo. the triphoephnte via the divhosphate, and . pa oo other stndlos have demonebrated that 11 is the ] i } triphosphate form of 4° anido-3 -deoxythywidine
So which irs balieved Lo be effective chain
Cv : b terminator In the reveres hranacription of " ~ AIDV, as svidenced by ita mffect on avian : d ’ myelobl satosin virus ane) Holonay murine oo : lvekaemia virus. This form slsu fuhibits AIDY
Nr reverse Lransariptase Lp vitro whileh having n
BR o 11%] negligible affect on tmman DIA polymarase 5 . | aativity. : y
Le ) _Bxemplas of pharmacentically a i asceptable ealte of the aompound of formula (1)
Co and 1ts pharmacent.iocal ly acceptable darivativer 16 tnolude bare nalts. eg derived from an ee appropriate haga, such ae alkall meatal (e.&.
Sl ~ sodium) . alkallue earth metal (e.g. mognosium)
RE © anlta., ammonium and WX', (wherein X is Cy 4
Sa alkyl) co Bb | 20 "The prasent invention thus further provides the nove) pharmaceutioally scraptable i dexivativen of the compound of formula (1, . ) ~ . oo - 14 - or : | AD ORIGINAL 9
ER] Lm
. . . . oo Cua a. wr man ® aes em PET fe Al vi fi : . i Fyne ’ ’ ae A Lon “ wt > ! ’ } : a « he rv ie a Toa A y ). pi AE
RES doe ET eto ee co - SUS . 4 : CRA AE gs 0 CR gan i hl . . Ce - ee TY & ih E LE
FEU Te Co CE TIN or gy ge wh fos ' “ TA RES EE ade oo Sh A : Neg peste. ne oy Ta : : ather than the tollowing & dertealives, osmely ; monophoiphatss, diacd ium mencphios pata, 2- aymnoe thy L nonophorphate triphornhinte P-
Co tolnen: sulvhonete, acatate tyripherrTasthyl
Po b snd’ me bhnuocolphonste deyiyativer ar where the
S741 je lioked to sm Turther eneleciide or nuglace id: dapioating,
CBpaeaifie axsing las of pharmacentically . 4 7 acoepinhle doerivabtives of the compound of ep 19 formula (1) bhal map be used An accordance with : no tha proecent Invention tuoinds the o~nosodium “i,
Ce sald: and the following b- eatera:
Te monophosphate digcdium ronophosphate
SE dighoerhate: triphosphate: scstate: 3.mathyl- 16 butyrate, catanoata: palmitata: 2 -ahlore con bengoats; bhansmnoate: 4-mothyl bansoaim: hydrogen : / succinate: pivalats: and moaylate, - :
Le ol : a BART IN-3 Aan vihrpmt {He Cr s rharascanticonllv arraptaiie dertvailes (thepscf soko 20 (hereafter reforynd to AR the agtive .
BEE oy Ey fd ingredient). may ha adminipnterad to baanps for ir } : . prophylaxis oy treatment of retroviral : . HE ' ‘., . . ol : oo | - 16 : i | : BAD ORIGINAL I) ' :
hoo Re CEL ten ny AES Lo ‘ vy . Cr . JEN FA oo ds Chi ET ins
Bidet Uo 0 Te Ee eR
RAN LE ip AYR, SAREE hr aT ee ee TE : EN BE po so Re in] a | Rog, LE an AR : , . Juha " . ACER Lin
PEE CL REN oo of
EAR Te Con et
OE i | Le "a . : : 3 oT infections by any aAvitable ronte including oral, rectal, mnenl, topioal (including buccal * and sublingual). vaginal snd parenteral (inc inding guhoutisnaons, intramasonlar, 5 Antravenone and tutradarmsl). It will be . appreciated that the preferred reonte will vary
Co Co With the condition and sge of the raciplent, the nature of the infection snd the chossn . NE active ingredient, " \ . co \ 12 ~ In genera) a suitable dose will be in the
Sree t range of 3.9 to 120 mz par kilogram body welght nd n of the patient per day, preferably in the range
Ce of 8 to 9@ mg per kilogram body weight per day ol Cost !
Vi \ a :
A } and most preferably in the ranga 15 to 60 ng ;
Col . 16 per kilogram body walght per day. The desired
Che dose is preferably presented as tw. threa, ny Th, - oo
CL four, five. six or more sub doses administered ;
Tr at appropriate intervals throughont™ the day. pw
Lhe These mub-doses may be administered in unit od 20 dosage forms, for example, containing 10 to : sh 1602 wg, preferably 20 to 1000 mg. and most
Ci Ce Lo wl preferably 5 to 780 mg of active ingredient iu) ~ : : oo - ; chai el - 16 -
Co oo | GINAL a ; os Bh de Ek LE : Tv, WL i amas = ’ Cay i CL
TREE ve * CL
TRL Te ped
EL . go
Chri af : :
Cpa
Ei cr ) : hl per unil doenga form. i. to CH Expariments with 3 -azido-3 -deoaythvmidine suggest that a Mose should be administered to achievne peal plasma concentrations of the } b active compound of from about 1 to about 7H uM, pretershly shout 2 to HQ att, most prafsrably : about 3 to shout 3P uM, Thie pay be achieved, for examples, Ly the inkravencus infecticn of a “~ 3.1 to BY solution of the active Lgyrredlent, vy 19 optionally in eatine. or orally siwminietered an
EES a holue pentnaining abont 3 to about 1667 mg/kg
Cae : of tha active ingredtfent, Pe=agirahlie blood
Co levels may he maintained hy ao continuous . - ’ infpticn te provida aboul, 3.61 te atont 6.0 £0 Co 1b ma /Xg/ hour or by . Jntermittent tnfusionm
Ll . Co containing about 9.4 to abont 15 mz/ke of
SUE Ca :
EEE the mative ingradient
EE . ‘While it is possible for the active ingredient to bea sdministered alon2 it le vo 29 preferable to presant it as a phevmsosutleal . formulation. The formulatione of the present
Co invention compriane at lasst ona active : - 18 - wa 0 oRiCW fas - BA bo y | Ss -
SRNR oh ie ash RRR AT oe BAY ee RR Th RAE Ta a eh al sir
BAR rr Tn TTL Sn RETR) Arr SET ae RERTR Se e A e R vd ho LAR hae i,
Tis LE IEE wk CE cone Ea ne Lt {ota Wh 2 i Ser
Hanan Bo flee « Co AEE gg
Eh CRE 3 : CNR oe dy 2 dnl i, : : Ay Re] rn wey SR RR Cg
CA T pA - Co Ag
Ra a ; } ‘ . i Cx E . oo he SR . : or ~ belle } . 4 . Co i" Ca we
Spr Cg cn TL .
Co Formulations of the present invention 4 a auitahle for oral administration may’ be
SL Co presented as diecrete imite much an capsules, . cathets - or tablets esch containing a
Lo 5 predetermined amount of the active Ingredient; , . As’ a powder or granules: ag a soluticn or a : . LE . ’ : { ’ sudPena Lon in an aqueous or non-aguecne liquid; : or: ans an oil-in-water liquid emulcion as a . . bolus elactuary or posta. Oral formulations = i pa to ’ 1¥ may further include olher agents conventioual -
Soh. x 3 oo ing, the art, such as suesteners, flavouring
Re :
Sie ’ : ght and thickenara. -. Co . KS or ' z 5,
GT Co A tablat may be made by compression or
Rr © moulding, optionally with one or more accessory
Fa Ch - cued
Ke » Coat :
CE Wo 1b ingrédients. Comprampsed tahletr may ~~ be
Phe J Ey : :
RSA Shenv, * , fob prepared by ocmpressing In a sultabla machina . Lo cea Hs \ fd the active ingredient 'n ap free-flowing form
Se sugh as a powder or granules, optionally mixed oh \ with a binder (e.g. povidone, gelatin,
Sr Vo Fei
FE i \ T 28 hydeoxypropylinethyl calluloce). lubricant,
Cod CN el Co
Shiver , . inert diluent, preservative, disintegrant (e.q. :
Le, , 4
IE \ Lot . nT sodium starch glyeollate, vrons- Linked
Pe : \ RCS cred \ 5 2 ! \ } i ' . . .
Ea ‘ Li rN
Wh RE
Sa x,
ET aE ee
ETE ot : r-
Coa | 5 le BAD ORIGINAL J
EE I. A
ER a mnt ee a AE ne lid peat SA he eC iow Mo nF eh ea saws se
SRI a Re TAA ABORT Flv oli Ee rT Sn a IER a © aN PR 140 - Ei A ih rift. 3 Sante Sa at co : wo . A an Vi. \ i SG LA» rt ye ame RR lta el HR : : CER RTs Tan
SUERTE LE TM Haw
SE Ce Cee ES RRR
CT marr mr re . 7 we g - : povidone, «rosa-linked sodium oarboxyrethyl cellulore), snrfaca-antive or diapersing agent. : a Monlded tablets may he made by moulding in =a
Co suitable machina a mixture, of the powdered
PH B compound mnietenad with an inert liquid
CL diluent. The tablets may optionally be coated
By or .soored snd may be formulnted sc as to
LL provide alow or contvolled ralease of Lhe
Pel active ingredient therein uvelng, for example, oo 1A hydroxvpropylmethvlcellulose in varying proportions to provide the desired release -
L profile. 0 A ; . Formulations euitable for topiasl : administration in tha mouth Include lonenges ; 16 comprieing the active ingredient in a flavoured
Chere ; , basis, usually sucroge and acacia or
Ch : tragacanth; pastillen comprising the active
Lo ingradient in an inert basis such as gelatin i and" glycerin, or sucrose and acacia; and
SA . 20 moitthnashen comprising the active ingredient in
Tro a suitable liquid carrler. . oo Ce » } . : Nasa wea
: po : whee een RESET NE ed
Fe Riis sn. . : Co wi) SR EE A or . 3 . whe Lh g ob , + Tha 0 on ¢ Re SY
Pee cL Eh 18 - SU | Ses Shoat me Cohn HS . Ce TR i SR
Tagan sy WT REE CE ee
Role, oo es | Tae RR
BAS SO : oo . ; ein Sr | | i
Co.
Fors lations for ractal adminiabvation way be presented pa os eappopttory with a endtable base cawbricing for eeampls nocon butter or a salioviate, b > Warmulatione suitable for vaginal : oo adminietration may he prepontad ss teogarfes,
EX tampons. cvasma cole, pacten, foam op apray . Ce to formulation onntaining In sdditien t3 the eo
So ANE " . co avtlve Ingradlant ench ne rarvrisrn ap Are known oh . ’ ip in The art to he ap ropriaste oo 7 Fovsulat bong auitahte for parenteral adminletration inolnde aqueonag and nan. aqueous } lsotonie mtar)la intection molntions which aay : : aontatn anti-oxidante, buffers, bactariostats ne 18 and. anlntee which vender the formulation
To So frdtonle with the hlpod of the intendad :
HE recipient; and squocne and non-agueoue sterile
LL * suspeheione which may innlude suspending agents . CL Aa. .
RTE sod: thickening agents The formulations may be :
Re, Cie Cy
Gg 7 TL 20 presented in nnit-dose or multi-dore gealed - we Co 1- containers, for exampls, ampoules and vials,
CERT cn . i kN es . me Sow
Ln . Le . a i
CL ST
Co ie BAD ORIGINAL 9) . . Lh | | -
Wepnoo pains 0, rR Lad an ath Lo To TEE a eq AR al 43 JOE mR
SBR CT ERR Te DE Be em el et tn LE kha oR ginger gh t -Hetub REIT Pr
FER Cb CEH . ot Ving gl NU fine
ST Cn ny SE THOR BE
Bee Co Ch : SE CARE Ee ET
RE po MPL oe LE LENE a TARE FL
SEs NS CTR he Tr CTT i Lo . “ds ;
LTA : ’ ea p ) ’ snd may ha Atoread in A franme dried
Co {lyophiliaad) aondition requiring only the
Lo addition of the sterile liquid carrier, for
Co oxawple water for injections. immediately prior ,
Ty 6 to use. RExtemporansous inlection solutions and - oo guspanalona ~~ may ba prepared from eterile powders, granules snd tablets of the kind
CL \ : previously depcribsd. : oo uo CPrefarred unit dosage formulations are
EE 10 those containing a daily dome or unit, daily
Yeo yt .
Lo sub~dose, as hereln above racited, or an
FE appropriate fraction thareof, of an aotlve hn eo co Ingredient. : . The adminirtered ingredients may also be
LL 16 used fin therapy in coniunation with other pu x os medicaments such BR CP {T2-hydroxy=1-
CL } . (hydroxymethyl )ethoxy Imethy1lguanine. B-(2-
SE hydroxyethoxymethyl)guanine (acyclovir), 2- a amino-9-(2-hydroxyethoxymethyl)purine, : iL ) 20 Interferon, s.g., d -intevfaron, intarleukin
Sr Si -
ERA - II, and phosphonoformate (Foscarnet) or in ub K conjunction with other imonne modulating -
Ca mn - 21 . ih SE
CL je BAD ORIGINAL 9
L . Le
- i
A pis HN : v5 1 3 Be ' 1. 2 k: : : i i! = 3 : 2
B ll -
Hl a therapy including bone asrrow or lvaphocyte i = 1 : 1 i tragsploats or medications such as lovamiool or !
TE. i ‘. thymosin which serve to iaoresase | yuiphooyvite i : ¢ mute rs and/or fanctlon ss in appropriate. | g i. | i
H 7 3 i 5 : 3 It shondd be understood that in addition to Ni
BR the dopredicots particolacly mentioned shove i
LL X . 3 M i
F the fTormoalations of thls invention may irc) ode a] - 0
Ml athe npenla convenhbionsl in ble arth wf i 1 !
Bb Ri x Foret ot boa hl
E : iu Thee Gompenpd of formala (1 apd its f Z
BR ol k4 i . V . . A iy 4 i Fharmacozint foal Yo oaoeeptables derivati VES lay les i. b 3 [1d i Co oo [i
I prepared do conventional manner, for example as n- 4 I k - dasoribad in Lhe following references, or by I J ‘BB melhodis analogous thersto: JOR. Horwits ot al. i.
Li IE . Re 156 Jd Chee hein 29, (daly 1964) HATE T8 IH. 55 Bata cb a), J Gry, Chew. 43 (15) (1978) | 1 8 i BO44 BAH KLAL Watanabe el al at., J. Opg. 1 [| LE i: i ¥ Chem. 40, A274 (L682); and H.F. Glinski et x. ii qa alo, J Chem. Bool Chew. Common. , 915 (1976), il 1.
RB
ED oo xX 24 as well as the processes dexoribed in the i 1 Esamplen, f ; i fl @ y at j i 3 1 3
A x
IES he os = Sun 3 : 4 Foe 5 a BAD ORIGINAL 9 i :
Oy a
Sb Ye LL Co ER Ls a : AA ne The SAE gop ch a a CEE Tn TR
Grae re he CAME SE ES lg, He An
TEAR A ave . ee . ERLE Beil 4 I Sop mE Cah e SR ja 99 “L
AAT Lo CER TREY pe
Sih i Ce
SRE oo : SE
Co : . The present Invention further includes a : procese for the prepavation of a compound of formula (I) snd pharmaceutically acceptable Co
Co derivatives theraof which comprises
Cot - 5 © (A) renching a compound of formula: . ' . oe | .. f on - } :
Lv t h A
Coe . SL RO 5 ~ . ) | “ | . \ J —— : . -
Co - Clg Ce “ Ca ils , . .
RT ] Sage . Cu ' noo
Cas el) Co i
STE EEE SE :
Sohn dat
Lh eo SU (Whereln M represents a prenuracr group of -
EN a :
SE | tha 3 -uaido group) or a derivative (e.g. #n
Sones . ] . CR . .
Lov estbr or galt) thereof, with an agent or under
Ten : ‘ a 2
Cael 10 . cofilitions serving. to. convert the maid : a TA " °
TL. . Shel ’ ; 7 eT pregureor group into the desired nzldo group; - n ; Co or 3
N a - - . A : N
Lo Co Be - 20 -
BO . oC
J nl pr = ’ : ; BAD ORIGINAL ‘ )
£ idk) py Hi Loa Gi Laat nh . Wt 0d EC SL Qo i - ar Lb ag: Ey Li 4 i N et panty oa La een Lem EE SPN TR A. Ti
Bsc eR en UFR il lee Ag oink aE oR Sond TT no wo Eel RH, CT
SE Cees : : : : Ch A ccm i FE
TER hid GE € ix : Nar Clay
TUR tgs ESE Ce Mig)
SE LT Ca TW Tt 0 ATER 4 rr brag de Si mamaria igi” - , or at Tg . - :
STARE od Coen . Tet
SE ou Sy Dare } wo Pale : TU EE
IRR a C
CRE Fb : ke "
Te < : ‘ Sh . : - . ast RB CO .
Lips oe a) ‘
Th LL :
RE o ov on! . .
Ce (B) rascting » nompond of fovmnln:
Cl : LL . 1 | ’ . Pe } ) oo Pl A (111) :
Co R
Pp o
Co j My r Co twharein BR orepresents a precureor group for wy fT : the hydroxy pronp, or for a phermscentioally A
CU ; b acdeptable dJdarivestive group theraef) with on SRA - Ce ’ a ’ yy
CE ! agent or wader conditions serving to convert SL
Coy , } | Re : : , ee t
AoA a Cy en oT FH Ce thg anid precursor group into the corresponding : i
SIRI :- dedired group; ov oo ca ' ! Tore [SE “. or eg . . a ; © Ce 4
T. i ii Sa SEC) reacting a compound of formula Coe Sr oe di ; } Lo CN ’ . Ce at Co 0 i» a
Soh . - FR Co cl CL Loi
A go A 7 on or ‘ °
LE J ~ 3
Lhe a . } L. - j . Pa , } \. 5 ' oa ‘ -, . 4 . [EIR Ta ’ Se - : 4 = ¢ TF
Cpe at } ie St . coe - i pr
Coe Se - 94 - BAD ORIGINAL 9
Ce - A bei - i ~ . Ga } ps ps .
Ce ! . . i ? . ,
¥ — — —_—
ER cibpat Test : crag ne : Carpe eas
SER beet UO pn Tie Pl dT CL We THER eee ye EHR CE pen “a
EIRENE Se en SC ve SETI me et Tay ee GEER ei ig Cg ol LE E& | EE Tee A Co EER rat
SN Shr Fr ion CSTR ‘ i ) ” 2 0). MeO
Plena Leon I « AH ah fet tPF Qn
EERE RR : : TOV aa Negignk OF 200
PIA NEARE ft Cpl : © oe [rn
Cea RETA le JA . . Ek . Sel a AR yt del Cah et Rd i 2h IE ET SHE
Sj Bra g CUR re
CE et EA - B CFE
FE = | f ] 5 Sl Col } ,, . i fo . or functional equivalent thersof, with a
Cy compound amerving Lo introduce the dasired :
Ld ribofurancayl ring abt the l-position of the
Be : compound of formula (IV); or ; i 6 (D) vesoting a componnd of formals Cae ol 5 = 1 on, t oN . oo
Cl ~ : - 2 opr - : 0 (vn) : . ~. 4 CE oo wk - a : : eh SES He oo fans 5 EO pi : BE )
TEM) nd 1 Lc i
EE ne : (ahérein R' is hydroxy or R as defined above), :
FRR Te Wo rio ; K .
PERege TL aT CT : » :
Baily . with an agent or under ennditions serving. to hE EE Lo ob To convert the sald compound into a compound
Er Eh :
Cd 10 according to the invention; oo and thereafter, ov gimtltanecusly therewith, effecting one or more of the following optional oo conversions: . 2 . . o he.
Ce Cig) Cl . oS Ce ae . Ol
Co CL oe . am - 26 -
CT ' ’ ST :
CE i : BAD ORIGINAL 0, :
Lo CE | :
PE Te 8 - So 4 . #
& C —_— —_—
Babine. afin ts TE ae cea he RRL hie a im i EE + REE GLE a et eee eb oe SOS
Een ER : CTT EE RRA Be
Fo A : a age FE HE TR a
Hee ge Ge « ose 74 SR RAE
BAL oA nd Tila i sep ol SA RELA sed, co
TERA . ve ’ ’ Dorr 5
Gk : : oo fi : (1) when 3° —agido-3 deoxythymidine in
Cl formed, converting it into a pharmaceutically
Ee acceptable derivative thereof, - . ’ \ 4 oo ' . \ (11) when a pharmacentically ancaeptable b derivative of 3° -anido-3" -deoxythymidine in formed. converting the ssid darivative into the ov Nr compound of the formula (I), or A At fferent
SU derivative thereof.
Co a In the above-degaribsad process acrording to
SER 10 * the invention, 1t will be appreciated that the
Co] ce precursor compounds of formulae (11) and (111).
Co as’ well am the above-mentioned agents and ney conditione, will be selected from those that
JRE i are known in the art of nucleoside aynthetic
Co KA - Wb . ‘
BLE 15 chemistry. Examples of such conversion ot procedures are . described hevainsfter for
Lg guidance end it will be understood that they : hg oan be modified in conventional manner
Ly depending on the desired compound of formula
Clk 20 (I). In particular, where a conversion ls
CE 5 :
Ce described which would otherwise reaesnlt in the oo Se | : oo v —~ . Ll " . rd + a. 7 oo
CE
CHT i So if a - 26 - r— | :
Lf Tr »
Ch Co BAD ORIGINAL &
& ATR EE TRCN Le RE Rn, oS EY wel Lm Sa SERRE ee wieeel He i EATEN
NEAR ET rr ed TT Sade : : . or Co eR ST ToL EE SY ee
ASE TL nT EH ge a Co yu ’ CRTERE + Wig PARI
SARE a SAW , Cy . fxg] AIO, CL ENE
Co a CHE or | Hi hk 27 Tele
SARA Bo : Ce wn AEST Te ean er rn Son EL ., 0 “i . oA Hl og ey - Co : Ta En ! rh.
En RA . eo : nel
RE : Wr ve
Chea . .- vo * . ’ ’ ) Ct undesired venctlion of labile pronps then gueh : ) . Fronpe may be protected in comvenl Tons manner, ‘ uith enhecquent, removal of the protecting - groupe after completion af the conversion, se 5 The. In proceae (Ay, the prone MH in tha : : compponnd of formless (11) maw renragoagt | for
SL axamp lo, 0 hoa bogen Ger chlorine hudpary or oo : sprains cn phony Toys ep
Ch _ Frifliaoacmet he lanlphonyYoey } ® . - 1a mebhareaniphonuloxy or portale galphanyloxy
Eo radios ) ‘ © Fer 1 he reparat bone of the copay ced of
Lon formula { 1) . a ono wid af fermala | i Y } i [¢]
Cn which the gronp Mode = halogen (ea obhlors) i 16 group in the threo ~oanficnration Cin which the
Cy 5” hydroxy ir advantageously protectsd, ag with ry AU : a tritvl group) may ba treatsd far example with i a Lo
Nip Lithium ov sodium azlde. The © threo halogen
THe Co 3
ST (eg chlorine) rtarting material may he obtained wT . : Geo ~ wel 20 fop example by reaction of the ocarrverponding .
Aaa So Se
Tepe ‘ 3 «arythro hydroxy compound with for example ne i ' triphenylphorphine and tetrachloride, or che alternatively by treatment with crgancentphonyl
Cie pe g oo oT PL LC
Bi . BAD ORIGINAL Ol}
Ce ) -
b
Bato afb LORE TL Te Ee i
Leta] Son EH Fue & HS Lo CL Lh 3 ENE 3 17 tt Av ; 5
EIR TE el Se i Coad cL Reet Cy he
FEOF Sh REY : -« : : oa BCR
EEL gbeca vl, el : Laet C Tne ls Na | RAE appeal Lr co a . To Mees A ¥
Sp es Cn Cem 1
BEET LT - aS
Hala : LE pT
BET . . - . . = - nr bo | oo ' 0 0 ; ~ " fa, ote
Lo CT hE
Lo Co . ’ : Pt
FEA | SE a . . ’ ' 1 i halide (eg trifiuoramsthapesnbplcoy) chlarvide) il to form a corresponding erythro !
Lo Lo . organcnn phony boxy compenpd ubiceh ie then ! 2 LL . halogen on teed Alternatively a 2 theso hydroxy
EE ’ ' ’
So 5 compornd ab formals (LT may be teestad,o tor
EE example uith tripbanvivhonphin., carbon : . t } Ce batyrabeomide and Pithiom azide Go dorm Lhe : i , Lt r . . ’ : !
SE corresponding NT -ery Lhro an ela compound. : ’ ! : Ln ’ i
Lo ; Ramoval of any protecbiygs ppanp peas then pubgeguent Ty be ef Focted oer ain hers
Cot . : oh . ‘ nd te i With regard Lo process (BY, K way vopregent
Cl sa , : : . a Probes bad hudpoxy poranp ooo. ary epter i
EE - i a aroun nie of Lhe type referred boo sbeve dn : EE - :
Co UE i - ’ srtiealarie wralb ory, “i cl Co relation boo farmnds (1) partial ! ALORY
ER ;- 15 DE an ellen weonp such wn tiialke inllyloxy i
Le Ne . FE : | :
Bei grony. ar. Lotmtyldimethylesllyloxy or. an } :
SE J aralkaxy group ag. Lripheoyimeiho:y : Buch )
PIR . tH P Pos ’ : a groupe mar be converted for example by . o
Co h#gipo lve in to the des)red hydroxy gronp oF, by :
SCRE 20 vrancen tert fea on, he conver ted to an a Co Jn . i x Loony T.
Sa fr . alternative apter group. of 3 -azido-3"- Ny
Cap dk ' . eg ’ : cred , . feet ‘
Ce diy thymi ine,
Cn Re - ’ ed Vo i
Bs ‘ CE !
LL : aE en HE .
Cl L . . . Me. Co
Cn REA 1 : : oo i : ~ BAD ORIGINAL 0)
Bi Mi ,
Ter thot
AEE Ln CT : : CF s Se ERG
Chiba oo Te : BAT. Se EES
Rb CL ST 0 sr Cem SEN
AEE a radi Lit : : EI . , . BR
A re fT WE : ee Llgqy LE fd a CH Y Sm
SE WE aE Cl Co COTRMA
Hus ie Se Ta Sipe OL Ie
SERRE : EET ’ . go
HORE | Ee Co
Cet LEE : Lo CT
CE : w : TART ey
Ci wr Ls Cc
LL i “With regard Lo process (CY), this may ba a effeotad for example toy treating the : + : appropriate pyrimidine of formala (IV) or a . £ . : pen . v ok salt or protected derivativa theraot, with a
Sh Bb compound of formula E
Ce i ;
A } : . igh ra 3 oe vo Be ep arena mean SN Sh . + . pat Ee ~ Coe : ot . VL - : , EE :
Ss SEG 3 SRE ib wor Sor Co iat et
CR SE B BN
Cf Ll eT (wherein A represents a leaving group. .8. -an eRe . Lend Lo +
Sal CE IE od
Cp orn agstoxy or bensoyloxy or halo, eg chloro group el
Cnn So as . 1 Co
Caiheseg 0 Red, and: B represents sn optionally protected - Th
RE ey i - ©
Cl ge fe : 1¢ hydroxy group eg a p-toluenesulphonyloxy :
Cl SEE EA : i sroup), and subsequently removing any a an B
Cop a CL
Es \ protecting groups. a co HE . . TY 150 Sy
Ce X: Regarding process (ny, BR) way represent. a } tL Lo . \ > . . . a . - ho precursor group 2a describad above for R. in
NE | ed :
CoE ar ’ = Co Hi .
BAD ORIGINAL 0)
CF cats he ) is LEwia ’ Lo - ab ho to To
GRAPE a Tg QIERE uh iy i CULAR Ee HE Bulh. cn Sg pail aad bi...
Fercitelnder, CY : Cast SL cot t JE CARN gE phd we TR LT Cr SAT agg hep
TH gs RE se = ! Ji “AY : LW ' [a ARSE . ; ot ot 2 ART oo ile cas EY
Tule oo oy Len Sods ride Foo
Wengen To co So Co Te lal Lo CE By
SE AL : Lede . es
Tram se Co Co
CL formnlae (117). 3° -Anldn-2"-deoxvthymidine may
I» \ then, for example, be obtidned Ly reaction with
GT \ fi, oo
Co \ Aan alkall wetal sxida. o.g. lithium agide, ik advantageously in an appropriste solvent such :
RK a , . | . i ~ a 5\ h ae wort MF followed Ly anid or haga » \, hydrolyveis advantage-uizly under mild ho : condi tiong :
RE NG : 3A AGA cdeoxvibymiding ma v he converted oC
Co ) inte a rharmacaulically acoptable phaephate or a © 19 «lber aster tv renction with respectively a :
Ln © phosphorylating agent. e.g. PCIs or © an
ELE appropriate eatarifving sagen. a.g. an-.hoid
RE : halide or mahydride. The compound of forkula dg
Fiera Bo : i wy EE 0 Including enters thereof, may ba cohverbed Co
SI LE 16 Ante eharmaceutically acceptable salte tlhareof Ib
Sg RN apd A ii . . EY
Pena ’ ie : LE : 4
CEI) 1h200nventions) mannar, o.g. by hreatwant: with Ww at Co CI Cnt ¥)
SN AR APPTOpriste bane. An enter or salt of.8°- .
LR agldo-3"-dmoxy thymidine may ba convarted = into
FIAT the parent compound, w.g, by hydrolysis. ©
Te 280 The tolloulng Keamples sre intended for ° : i. ui illustration only and are not intended to limit
SO Ch } ~ a.
Peer Lk Sng . So
Chl Ry CE. :
CoRR cu my : a
SEE TH CL oo .
CA la - 36 :
CEE Eg
Logo Tog RE CL . co cel . Sy SER £0 . So .
RAE Nd SIE LT : pine fins CUE Neg : r RE =»
LT - Ce BAD ORIGINAL“
Sots yi Ce } Cen ° ;
CR So tT _
be RW ie 5 Ss SAGE Eh pha i Fs CUA DE sen AE a he Coe EAE ee es siranasabid io, oo
Sen ERY Lh bE TEE FA Le Ee todd AE SANE Ee go
Ta Ce Co UNS em bo ERY Te eT - AEE Wy TRE AEE
Re Ee #P V bare S eg TNE hy oO . .n FTA Mn \ EL es WL Ee
EIR, Tee Migs So fr sy LOST re Eu
RE A Lan So RANG bsp ip Fo soupy ln Arn Cn . abe LT
Spen oa Ag Ly
Ee . Cy Teen
SE te oo ow
SEER CE Cn :
I . a Cf - the ecops of the invention in any way. The , 1
Lerm ‘active ingvedient an used tn the is. Examplas masns a compornd of formals (1) or a rharmaceutinally accoaptabie derivative thereof. rE 5 Bxamyle 1: Tablat Form lations 4 ~The following formmdstiene SN wp) nN wera prepared hy wget granmiation of the {npradiente
NN with » eolntion of povidone, falleoaed by - a . a addition of puenmeiom ctanrate rnd eomprassion. . . + 18 Formulslion A LL
CO Col : ng/tablet wpeg/tahlat nL oo (a) Aclive ingradient ohne wha Co
Cae (b} lLactope HUF. se ne
Ga Cer . .
Ce SE {q). Povidone BFP. 1h 0 Co
Senta 16 (d). 8adium Starch 20 12 7 a ‘ ol a 3 . Pn ' . Sh | or ' i
Le oo Le, Ulyeollnte Ch
EL So (8) Magnesium Stearste b a
Ce SE ey £6) 200 So
Shi 3 he Lo ¢
GenE oo Co
Co he Ln pr =
LE TRL Le rh hehe NY "s . }
EA SR Nes
SRE . ¥ ERE : SL
LT : oo it Te : id - I = pe So EL ~ on . pr NH )
CE a BAD ORIGINAL OW +
RRS vA Twa re - hl i Com ‘- ro
EEA mT I. “
Hd on id a Le Pie =a’ Nagi ew : : PE ToS I : hE pe Es CUTERGRE ENT dBRL ae cE I AEE A i
DIR Aad LEE : Lo SPE WRI dA UR Get ENT
TART Ln oh oe Cede “Beas bl ae oo oat ad i - Let : Bae
GEE A " Coat
SE AT . Se I nL
EE Formulation B
Sn mi /tablat mg/tablet oo Ce (a) Active ingredient 260 260
Co ! ~~ (b) lactose | 160 - . < 5° (a) Avicel PH 181 60 24 . 2 (d) Povidona B.P. 16 9
Co (&) Sodiom Starab a6 12 wn Alvcollste (f) Mzgnesinm Stearate 6 3 _ : , — a — em. ba 50R wa . . - “5 iS : / .
EL Formulation OC. oo “hl - u mg/ tablet . hy
Ci Adtive ingredient 180 “
Thin Cd RE : CL :
Co : Ligtona : 209 ~ . . " ’ Ja
Ce 16 = Btarch 59
She Eh : Co
Lo . Pov ldone 5 Ta
SIA Po RS Lo
Roe hen . Magnesiuw stearate 4 Sn :
ST : EI A ee an a ve
ER Fe EREE Cd he ) © %The following formulations, D and F, . were
CT 29 prepared by dirsot oompresilon of the rdmixed Go
Cm .. : so lngiedisnte. The lachors used in formalation F RR wag. of the direct decompression type (Dairy oo . Créet - “heparvox”). Co a Be oo FH : - 32 - HE
CE Nl re Lo
Celi Es wr ; J or Ee Wo ER N
CER Sl : pAD ORIGINAL lo
LO SL RT : SE b Apt wf i - > Les - ey . " . . “. ne bed a. . La
Bama. ren cule Ye RERIER Te frp TT Dy EE et RR EN 5d Be A OA ce Tih ve “ 3 po ak ! - : . Tor Sng Ae 3 - ANE Sl pr ’ oi
AEE Lf Re o : oe TING, pu Fe pags JRE RE TRA Lag Lo
Ri rors x L : : SE P \ 2 dy . : yen TO - We oo Ch
LT Wy wt Formulation DB. i mg ‘eapau la
Active Tugrediand, whe
Co Pregelat bypaed pa) C15»
Cc bh HF 10 ee
Co .. 403)
Co Formulation
ToL - ms ean le
Doe Active Ingredient wR
E Lhaghoaa thw)
Tenner AT AY J an A
AC vl) 144A an ee ey -
AL Ki < we
I Formulaotiom F (Oontvafled Weloass Forpalabion) Co i. . Co
TL ’ ~The Lovmmiiabion was prepara ty wet . Bs J E : . . granulation of Lhe inprediante thalonu) aith a co golution of povidone faolloged hy the atitition .
Lo 16 of magnesiom atenrate sod conpresalon.
LAO tal : : - eG i vo uss tabla ; cul a : : Pa) Active dugroedient Ful . a . “ (HY Hydyvorvpropylimathy lee l balan. tie A vo
Ce co (Hathoce) K4H Premiom Co wt = 28 Sle Lmohose BUF. ny : hee oo a ld) Povidons BP. ry
EE Fe ~ {&) Hagnasinm Stearsato 7 i. eo TE rn ion
Si Loon as | :
Claw - 33 : :
So ER . 3 : i . . Teun : | : PA - '
EE Cd TR : oo - ; . x2 j Te oo rY i D -. “ : : BA | INA . } , J gAD ORIG
A So isis part Cy ex oe) $s. ne > a LE att ni Ve , - a :. . nL Lo a 3 Sn, Co Dale Ree big, 3 hi he ay SLUR ET aE. co HEE Tt a 2 gp I PE Amd Li : CLT PHT STOP a a pe LS
San ; CET : Ea - Co Lee %bgqd CT gate RE } Co FE ” PR = , : Lo gy Wel . “ ¥ oS 5 bil ol o
FL A He ws de eee Co EE TL TT yaE a . Sn Ct iy rug release took place aver a period of about, 8-8 honre and wae complete after 12
So hours, : vS ’ - Sn : . i . \ . po | ! ol Example 2: fCspesule Kormulationy
Co 6 Formulation A : - ' A capsule formitation wan preyarved by
Co admixing the fngredispte a7 Forpmlation Din
NG 2xample 1 abhave apd filling into oo bwo-part oo : havd colatine cappode. Faamalation 8 (lofra) .
Co - 19 wag ‘prepared in a similar manner, oo ;
Loo ‘Ferpulaticn = Ll ily bh . cE - SI . MZ Capt he
Co (4) Active ingradient A oe .
FE Cory v . i sri . » {B) hmclase BOP tis . rn Lod 16 (a) Sodiom Shavel Glyeollata oy :
So oo (1) Magnes iam Stearate no .,
LE ) — Te :
Coe : mE " Co : ae REY 40 . A,
Ee > . ~
CL rn CEA : “
Ee Ce Lo Lo
SEE Lo “7 oo
EO ~ Pork al i : ; :
Ll Lo - 34 - sha iy TE .
GU LE sR Co fr Cen ht : CY
Cl Se . ~ An “ . oe at? } .
arin ga oo EE eT laen hee wy So Hest Char eet ey
Bae CO . Ee Doggd
Spl En | Se SOIT
AE at 5 7 EE
SE on oor nn be Co nl Lo
Co 1 : )
FL Formulation C - mig /capsule
Co (a) Active ingredient 7269
Co | (b) Macrogol 4000 BP 66 : 6 a | a
Co ol . : . o. Capsules were prepared by melting - the i» : ; : 3
Si Co Hacrogol Ad% RP, dispersing tha active
CLs ingredient in the melt and filling tha melt
EET Lo : : vy
CES ee . into a two-part hard gelatin aapsule. :
Tras RA "a
So - 7 18, Hormulation D
Td : oo AA .
Fi 0 ¢ B RE Mg/rapsule : a SEE SL i POT .
Got Active ingredient 250)
SA : et . i. So a . dT Leaithin 100 : ino Arachis oil 100 in g a No 16 a } ANG oo . LER Ta Ea aii : J
SE ig re Ce i" } 3 £ . } . .
GET ' Car Cr
Selina £.Capsules were prepared by dispersing the si J motive ingredient in the lecithin and arachis
CETTE Ee : ;
Shas OL oil and filling the dispersion inte eoft, oo SE , Cd Co ’ -.
Cl elastic gelatine capsules. .
Fon hy Co A
SARE ra Co HT Lo
Sree ML SR Co ud oo
LE Ce SR ro A
LE Es SL : wo :
ETE IE v h, ~ fn BOAR i, ob EEE TL a ale 7 Rpt RRR Ld ih a
BR Bs dito tie 0 ee tt wif Fi RT PE Same «TFET A Nr Ete ©
BERRY Be er BL Le UR Ry JA Sh Com MY TNT TR Ls THON 6 Hed SRR go mR aT ER Re
ROIS Eas nA ’ ¥ Vt Saban Te ty ERE)
Fe ER “id et 1 He . . . ’ wd IE n : Le : VN Y g fx oe i
BeotoRLEC CL CEL Ls SEER TR kK: A dat Co ‘ ! : ym : a : } Ay TR % : eer oy Sa : : , Loo
Formulation E_(Contralled Release. Capsule)
Th ~The following controlled relesss oapsule
Ha formulation wad prepared hy extruding ingredients a. b and 0 nsing an axtruder, followed by mpharonisation of the extrudate and oT
Lo drying. The dried pellets were then coated
Ce with release-contrnlling membrane (d) : and
RN NS filled into a two-piece, hard gelatin capsule.
Co ] . mg/capsule
Cn 19 (8) Active Ingredient 260) an (kb): Hicroorystalline Celinlose 126 ad Co (a) Lactose BP 126 oE he oo . NT , Co : ! ann Co (d) Ethyl Cellulose C13 Ll .
WEE ci mmm tel i LSE Low 16 Exampls 3: Iniactatle Formulation :
I a . as God .
WEL ew Ln oY SE : nn
Gemma TL Formulation A. Co
EH . Ln Co
EE { Active ingredient 2.200 g
EAT x “Hydrochloric acid Lo Co
LY =” solution @.1M ~ 9.8. to pH 4.90 to 7.8 ;
CRT So Sodium hydroxide Vo ¢ : wl _-8olution, @.1H © q.8, to pH 4.0 t0°7.9 ” of Con CE .
Sl 20 Starile water 9.8. to 19 m1 oo cob Hn, Cg DE . Si A Car ’ 5 he 3) Co
CH L Vig ’ - 38 ~ BAD ORIGINAL oJ
CM 2 . : Ce LY . nl Tg SL ——-
SEE aos TE . ait Py a Kh si, f Fi
LH h - Joy
Ll CR le oy Los . Co v
I ing EEN
Fa ia gn | Ce CTRL
BES Ras, : ; 5 Lae we IN te 7 3 . ll al ER a ps ; . Rr
WEEE Lo PAE . EE
Fah SE -
Ll a. The active Ingredient wag dissolved {n most oo Of the water (36° _gg0, "MA the oH adiusted to, i : | between 4.9 ang 7.5 WIth the hydvoohiorte aos
OF the sodium hydroxide ag APPropriste. The \ 5 "batoh wae then made up to volume with the water . \
Co - and fi)terad through a ster lan micropore filter : - into » sterile 10mi amber flame vin) (type 1) . \_- and sealed wit 8terile closures and overesals.
ER Formulation p,
Ll 10 Active Ingredient @.128 g
Lo . Bterile, PYrogen- free, pn 7 Le
Le “Phosphate buffer. q. np to 26 m1 : A LC A :
RENEE | Bamele 4: Intramuscurar Indection
Cg Aotive Ingredient 3.20 g
Ce Bensyl Aloohor 010g
EE 16 Glycoturel v5 1.45 g° ho Water and Injection 9.8. to 2.00 1° my ‘ RE =
Sd Lo The active ingredient wag dissolved in ype :
Chesno €lycofurol. ' The benayl alcohol wap then added
VIELE ands. dissolved, and water added to 3 ml. Phe
CEE 5 :
Doane mL 20 mixture wag then filtered through 4 cterile o EE Su CT Co fi pf en oo Lo I
CA iA ,
SE ns i ’ I. } }
ETRE, - - 87 - a
Br Cy RR ., a co
De, Ee Ed I 0 ORIGINAL il
Sasi : : Vo - aay a . ‘ 2 wn 3 : CL
Ta on © se ggg wah : ye
C nioropors filter and sealed in aterile 3 ml
CL : amber glama vials (types 1). : = oo ‘Bxample 6: Ingradientn :
Co | Active Ingradient @. 2600 & oT 5 forbitol Solution 1.6000 g : LC dlycerol 2.9000 &
TE i Sodium Bensmoate 7.9058 g ena : Flavour, Peach 17.42.3169 @.0126 m1 | : a - Purifisd Water q.4. to - 5.0000 ul
Co 18% The active ingredient was dissolved in a : oo - mixture of the glycerol and most of the ’
Ci purified water, An aqueous solution of the :
Ea o ‘ modium benzoate wae then added to the solution, n Cl at _ followsd by addition of the sorbitol solution y
A La 16 . and finally the flavour. The volume was made 1 go 0, LL Co Co he up with purified water and mixed well. . Co
Ph EL A oo LT
ATL TT Rey el tor Cn :
CL Tr 4 a : Co .
SE TRE
Por | - 34 - .
Se en “, 5 I
Sh en ri
CR Ee . BAD ORIGINAL © . ) Hig «0 - . . . .,
b
SAREE BIhv anf 10 200 LC . iS bagless ooo kT . : " a NRA GTO, Lg wi lE au Sl \ Ri: ale FT al SWRA rE Td, Ee VC Le Yo Rh So & 5
BR Tg eR
MIRTRn. ue WR Sw eal SL gg gE bi dE Li I : Ged NEE pr Le AR CER Ee PAE 4 £23 AA a ER to Phat Eg 2 CN “E : Cig ewe eT al CoE Rn
RAL i wT pir
Foner oo PEA Co 5
SN y ce Ce Co
Lo Example 8: Suppository - gy ma /suppository
Active Ingrodisut (63 umit 262 :
Hard Far, RP (dWitepeanl JI16 - 6 - Dynamit HoBel) : 1710 i. oo 2026
TA The activa Juvredient waa used am a o povdnr wherein at lengt 99% oft the particles ‘ ware of R3 nm dlsster or Less.
SEE . C One- FUELED of Lhe Wilapaol W156 yas melted in
Si : 18 aidbesm-inckated pan at 4R°C maximom. The ol Se ani . “ly £0 . } Maa
Ci - afgsive ingredient was gifted throogh a 200 - um
Ce aleve aud added to the molten base wlth mixing, So
CERT vging »'silverson fitted with a cutting. head, le gata CN Sg Co SR
TERRY hy uatil a eancoth diepersion wea achieved. =
Ee go : oy fant eS g 16 MAlntaining (he mixture at A670, the remaining
TERA PRR] . B Sn . . .
LEAS Tie Co com SE . : wHiterssl HIT wae addoad to Lhe vuzpension and os cat ne \ RE i Sn i hE Cg :
PIE ‘ lire] te eanure n bowogeoous edx. The entlre hE - Bugpe neon wine passed through a ztdlum etainless
Pore Es red a . }
Ph ae a TE
Gen gtewl ecreen and, with coubluacas stirring, was
Eyre SE ae
Sima ol 20 allowed te cool te 49°C. At» tempersture’ of
PRE EEE
CEA 3 5 . oA ~ 380 to 42? 2.428 of tha mixture / wae
Che . A oo
LE CTE a
CTL : - Lo nL nt Me Eg - 38 - Ty oo
Po TR CoE So
I RRS LE et
Lola THe Sug . :
Cole CE RE r
PT Fi Jie BAD ORIGINAL 0,
Ponape Ce Rn oe
Lor - TE cf
- . ~q9 a - filled inte suitable plastic moulda. The . [a Vr wl suppositories were allowed to cool at “boom hE
Ee Sh teperature. . . ot
SAR Example 7: Eessaries | oo
Ln EE 6 . I oh Co : Aative Ingradient 83 um 260
Co | Anhydrate Dextroee sg
Ca No : Potato Btarch 383 aT | Magnes Lum Btearate | To
Se | : ma above ingredients wers wixed directly oo : and ‘prssaries preparad by direct compression of
Ge : the, reaulting mixture. Co wi TA Baample 8 ju 3--Aatde-2" =deoxyzt:@= ; - To a solution of 3° -asido-3" ~deoxy ok © thymidine in pyridine (°C), octanoyl chloride ne - Ea (1,2 equivalents) was added. The reaction was : cn allowed to warm to room temperature. When tla ern Ue ER oo | - ee - - 40
Ci EL Ne BAD ORIGINAL 9
NE Ea ,
She Ta Ty
£Cqqy (CHOY 5 HeOR: 2831, cn midica aol) Ind jeoatead aampleta peact tear, the gotnt don yap poarad onto
Joa water. The aguecng phase wan danantad
The vesnlting nl) gar chromatographed on ail ioa t gel with CHOLL Hel, The tilla componnd wan ahtalned as an ail hy evaporation of the polvent from the appropriate fractions,
COHN: cal. (-H4 OR H-F 09 N-17 RD faut, C-F4 AT 1-6 08 N-17.686 1 d7 a6ca, in Tg gota, 6H), DO 6.0306 10M, Ta4.6.4 200.20. 30 And 6 OHNE 4.9-3 sim dH. 4m, O02 3.2. 1m A020 and (CH, of aetanovl)). 0
L.BICA. BH Ig ool Oa BH), © 1.6.0 Aim. 130.5 oatanoyl LOH, (CHG)
Example 9: hi-Acety)-3 -azldo-3 a deoxvthynidine
To a golution of 3 -azldo deoxythvmidine (298) in pyridine {Html at amhlant tamparatape, acetyl ahlorvide (2.1 agoivalents) wag a. lded Tha reaction una ativred top tue 41 : Cw
AL 9
BAD ORIGIN
. Ca
20a henve and kept abt 3 ta & 0 for 20 hemre I+ was ponrad onko bon yater gllh eb irring. The aquaong phaaa wan decanted, The oily product ua diasolved In watar and extracted gfth gatar
TTR TB times), 0.5 HN hvdrochloric acid, water ~~ (2%). snd dv led over masgnagiom anlrhat. The solution ase filleved and avasporated in vacuo
The residual oil wap diaeclved tn chlorafarm, applied ba a asidlica gel oolnmn, aad Flash to chromatographed ve tng ny mest hope |, in ohloraoform Fracstiong with proche Way avaparated and the «ofl was chromatographed agaln using ekhyl aceltsalte: heysna (6:4 v/v
Fractions with pradact ware evaporated in yaoua ta oa whites paella ‘ m.p. 96-9289 anl. (468.6 H-4. 89 N-22 8% fad. (0-468 67 H-4.94 N-22.59
Example 14 : "The following compounds ers rraeparad aacordiug to the procedurs of Examplas 8 or 9 as appropriate from the appropriate sold halide or - 49 r
BAD ORIGINAL - (
3° —Anido-6 ~B3-benrorl 37 -dacxythymidine cal. C-62 BR H-4.77 N18 41 fru. N-63.81 H-4.72 N-18.46 m.p. 64-5070 6 3 -Aztde-- 3 ~deoxp-5 ~@-plevalovithrmidine cal, 0-61.27 H-6.03 N-19.9) fnd. C-H1.07 H-6.,056 N- 19,82 nm. op. 99-1870 3° -Ant1d0-37 -daoxy 5H ~-F-{3- 1& methyThntyvry thymidine pal. C-5@. 24 H-6.13 H-19.62
Fad O-R D7 H-K. 11 H-19.49 : ST. 480A IH Tg oo 1. 2H% BH), 8.13%, IH, 1°HY, of 4.6H-4 16(m. 30, AH and 6 ouzy. &3.8- 4.1F(m, 1H. 4 0), dn a-1.780m, AH,2°H And 5 mathine), : rr
OL.88(43.30,0g gv. 203, bCHZ) da. 00a. 60, 1-6 4Hz, methyle on 5 butyryl) - 43 . )
BAD ORIGINAL 9
E fe -19- BLAS
A A. BE <q fo J» BE” 3'-Azldo-3'-deoxy-5'-Q-palmitoylthymidine cal. C-61.67 H-8.57 N-13.85
SEES find. C-61.85 H-8.59 N-15.7"
Hf Al . i 4
Co 67.65(d,1H,Jg (=1.0Hz,6H), §6.12(t,1H,1'H), 64.5-4.05(m,3H,3'H and 5'CH,), 84.0-3.8(m,1H,4'H)
RY 62.35-2.1 1(m,4H,2'H and (CH,)1 of palmitoyl), §1.8 d, 3H, 35 ,=1.0Hz,5CHy) §1.35-0.6(m,29H,5'palmitoyl(CH,) | sCH3) 3'-Azlido-3'-deaxy-5'-0-toluylthymidine Cal. C-56.10; H-4.97; N-18.17 nd. C-55.88; H-5.00; N-18.09 m.p. 73°C /0 NMR taken in DMsO-d,
NMR: $7.95-7.29 (m, 5H; bH,cH,6H), 86.16 (t,1H,1'H), 84.6-4.4 (m, 3H, 3H, 5H), §6.2-4.0 (m,1H,4'H), 52.39 (s,3H,dCHy), 81.63 (3,3H,5CH;) 31_Azido-3'-deoxythymidine 5'-O-(hydrogen succinate) Cal. C-44.98; H-4.83; N-17.96
Fnd. C-44.90: H-4.77; N-17.85 7€ NMR taken in DMSO-d,
NMR: 57.46 (s,1H,6H), 86.13 (m,1H,1'H), 64.48-4.40 (m,1H,3'H), §4.34-4.20 (m,2H,5'H), §3.99-3.94 {m,1H,4'H), §1.78 (3,3H,5CHS5) . 3'_Azido-3'-deoxy-5'-mesylthymidine Cal. C-38.25; H-4.37; N-20.28; 5-9.28
Fnd. C-38.15; H-4.38; N-20.19:5-9.30 m.a. 253°C (dec)
NMR taken in DMSO-d
NMR: 67.45 (3,34, J¢ g = 1.0 Hz, 6H), §4.15 (£1,354 0 = 6.6 Hz, 1"), y
To §4.54-4.41 (m,3H;3'H,5'H), §4.14-4.02 (m,1H,4'H), 63.24 (s,3H,5'-mesyl CHy),
Ke ~ 51.79 (d; 3H,Jg ( = 1-0 Hz; 5CH,} - ’ “ < LL 31_Azido-5'-0-(3-chlorobenzayl)-3'-deoxy thymidine Cal. C-50.31; H-3.97; N-17.26; C1-8.74 : Fnd. C-50.16: H-4.1"3; N-17.13; C1-8.66 ; NMR taken in DMSO-d fk £11.37 (s,1H,3-NH), §7.98-7.43 (1..,5H;5'-phenyl,6H), 86.17 («+ 1H;
Jy ge 7 03 Fs Ipap = 72H 1H), 84.658-4.48 (rm, 34TH 0,
Jo 84.14-%.11 (m,1H,a'H), §2.48-2.41 (m,2H,2% 1), §1.64 (d,3H4 3g ¢ = 1240 5CH-)
HDL /I.MJ/26th February 1986 . ea — rte io BAD ORIGINAL = a ig cr . 5 . oo Batman ] | ) p Sath — — . = fl Pe - ) : NS 2 Ee _— " A Stara esse. €. a wo Cg tae ~~ - 15 il be
PERE a COTTREIY Dh EEA FU ER EE
SSE Es oC Co COR “lssihall tn fA FF * ee ET apr IR Vo bess
Eo oo 2 : WE : Example AL. 2.6 =0-Anhvdro-13"~asidao- a denxvthymidine
CL | 3’-Apido-3" -deoxythymidine (3.9%. 11.2 mMol) was mesyleted by the addition of 6 mwathaneesulphonyl ohloride (2.7 ml) to a - solution of the starting material In dry
CL “pyridine (2 ml). The reaction was allowed to
CS progeed at 5°C for one hour, then poured onto
Co ice water. The precipitate was collected by oe
He 19 filtration. The product (3°-azido-B’- ll Lo mesylthymidine were heated in an 82°C oll bath
Ly SUNLEENS forsix hours, then pourad intd ioe water. The
SET product wae extracted from the water with ethyl
LE : soatate. The solvent was removed in vagua and
SI 16 the resultant oil was falsh chromatographed on
CTY Co silica gol by slution with . CHO14:MHeON (911
Cn ; Co
SE v/v). The title compound was obtained am a iE - " solid after evaporation of the solvent, trom the nih leer appropriate fractions. dF 28 wap. = 184 - 186°C | Go
Fe ; “ : i: vn vo co Ch : T .
SE | ” 0 Cte,
ST Se Co - 45 - BAD ORIGINAL J Ct
RAE nity, 0 Ee Cn ee ACNE CET en Sn Th Ah nt Mail Ll nem ce ts
Bf nn oT Re sie
Re Cbs LE oo Co CRT +, SOR Race
TE $8 vy, Te Cer 2 Co t = & ay % i aly Es qu0 Ey 3 Ed Pr Jog ov : - LE i ' . . Lo % Ba) 5 tars :
ERE a SN Cn URS Bh wk Ln CL oR
EL Ch Se en
J Ko, : co : ‘
RET : :
Toad b sl . :
Cv
Wo . . . £ Example 12: 00 Aaldo. 3 cdotss Whowld Les r
AE , he : : ;
Ed (ue) 2.00 CAnhydrethymiding
Cha
SR Thymidine (Bh 4 g: 9. 30D wol) wae Adamo lvead
WH _ fr. he - oo : ) Joao BEX wm) dry DHE and added bo Nha i Co Le > 1. 1 ,2 Le EfIncrasthy Lidl ethy Taming E148) &
SEE do . 2.0628 wold (gprapnrad according tor they method oF a D.&. Avar., FV. Hel Chow fi, 608 ( 196) Thi } fe bore ’ fy po
ST aolutlon wag haslod nt TOC for 9 misutoa thew dT poured Like B63 sl pthonrol (KLOH) with vigorons oo Eo 2 12 stivy lug. Tha produst graclintstod (rom thle
Cla solution and wap £1) brad, The EEOW
Coben Va vo
Cdr RAE
HS suparaalant va yvofrigoratasd thon fittorad Lo
LoL an oe }
The oC 181d thes biLle compound. mp. -228 23@°, 1 "
Cyr Ea : Le
Codey LRT , I
ST | CR a ty ik a oA) 3. -Aaide: 3 adouxyihyriding a So
Col vy 16 “2,37 -@-Aohydrathymld ine ( nh gr 9.1116 wold
SE 0 : and“ Hally (29g 0.446 wal was ewsponded In : 3 aulxtinre of 260 mt DHF and 38 ml water, Fhe t a : By R i . : ! i
So rabetion mixture waa refluxed Cor & hours “ab :
PI which time 11 wan pourad Jute 1 Titer of wator, j
LT a Lo j
Cu C20 The aguacus goluflon wes exlracted with ‘BOOAC er CE : oo ' " : (3x 2% ml), ‘The ELOAC cutracts wera deled ae s oT v. SE . tf ek TL i | aA
Lei : Er D Gren x Fe . : . © i Lo \ _ : - 7 . . :
RELL alee oo CT REE ERR
Then ES | Cad Gee ame oR | | EE Hl ha a | i
Cee over Na,80,, Filterad and the BLOAc waa removed - oo — ee An vacuo to yleld a viscous oll. This oll wae
ST . stirred with 2090 ml water providing the title
Ee . compound. ap a eolid whlch wes anllected hy
LY 6 filtration. wp = 116-118°C J - Exauple 13: Hoposodium Salt of 3 -Aaxide=dl-
Co deoxythymidine :
Co (_.
LEN © Ly. Approximately la of 8 -azido-3 -
Can St - deoxy thymidine ans dissolved In BP wl. © of
FT | 19 distilled water. Ths pH was adjusted to 12
SE with IN NaN. Approximately half of 5 the
Co SE solution was freeze-dried. The title compound or was obtained as a lyophilised powder. vo «
EL Analyeis calculated for CyaH1NsiA046/10 NpO ed . - CAEL AE 3 v Foi a. 16 cali C-40.93; H-4.47; N-23.24; Ha-7.66 1 ;
Sb tnd: C-39.88; H-4.34; N-23.23; Mn-7.99 Co
AA . Example. 14: Freparakion of 6° -Honophorrhals of oo
Cope © 3irAaido:3 =deoxyihenidine CE i to 3'-Azido-3 -deoxythymidine (8.5 «, 1.87 mmol)
A wn af j Po
LL fo = i Ba co : " I. Ra }
Sop Si : ER - 47 - Ey :
Pl ST SOE | cei 5 ln, Lr A | BAD ORIGINAL §)
A . : Co , .
JOINT : . + : wh t _ . : 1 t" wan dissolved in 6 ml of triethyl phosphate and §
EE the "mixture was cooled to -5°C. Phosphate oxyghloride (#.686 ml, 7 wmol) was added in one portion to the rapidly etirred solution which :
Co fa . i. g Co 5 was then maintained at -1970 for 22 hours, An } Pp ? Ce TY, . co
Cy aliguot was removed and added to concentrated : | oh ammonium hydroxide. Analysis of thie samples on i
Lo TLO {eellnlose, n-ProH:Hy0, 713 v/v) showed no
Lo Z remaining starting material and a eingle .
FT } 18 fldorescent spot with lower mobility than the | :
Rei - Si nuoleoatds. The reschlon mixture was poured to
RS ‘ : So Ee : Co AR i.
RI . onto’ 20 ml of 1lce and water. this was placed Nn
Srl PR I. oo
Ee A Sin oan ice bath and the pH of the soluiion. wae Me
Ch A © adjusted to a value to a value of 7.6 by the ; he Vo a Co : of : - 4
Er 15 addition of 2ZN NaOH. The basic mixture Was wd - Co extracted once with chloroform and once with
Si ai : gther. The aqueous layer was again adjueted to Co
TAT Cort Sh SA J C Lo
SE so alve. a pH of 7.5 and concentrated in _yaquo to :
Gren bo remove residual organic solvent. The material ; : + , = . ; . SL . ie J
BE Li 20 was stored at -19°C until purified as follows: :
Tel CE Co
Co att a Co DE
SR CE Deactivated charcoal was prepared by washing : :
FEE Re de Cel cE i
SESE aoddnut charcoal (bO-200 wesh, 120g) with ' 500 Se
Hk Vie TW . -
Are Cy - Con
Loh xs 3
Lal igh a BAD ORIGINAL .
Ei PR FES A a 23 Pie Sgt Een a a et a Te Ln ALR isn Tae aA bil
RETO PPS A Cy ji TARR ee Fae O15 hh a Re
SWE RS nT a EE es i a Pe
FEST BL TLE Sie BG HM STE
EIA Th TTY TMT SLR CE Ke oY SE ey REN: Jey : Jared Ca LT ’ CEST : . leah To co EBs Jed Us HE pLLC Le - Co SE Con Red front £2 EST ESR en LE a Chg dh Sd a RRA Gg \ PRESTR ’ . eine VaR Ee [or
ST eA : 4 9. Ca ’ Sl . Site Foe i Bl ef UA ool WER
SEL LL : \ a ’ . Dt en el eo ; | Re
Toys ooo ’ or : !
Sr ml ef Ut NHCL, 3 FL of water, 36 ml of 3% a toluene in YE% ethanol, GOA wl of 668% athanol i and . finally exten lvaly with unter. ! Paactivataed charcoal (12 wl =f aA=ttled wer : b charcoal) wae nddad with sticvicg to the monophosphats wolulbion (B.72 g, 1.3 wold, 39
CL ~ mh). The supernatant wan decaated snd the
CL . oo charcoal wan washed uitl LED wl of yalbeyr. “The:
CNL nucleotide wen elubed bros the elinyeanl by 180 washing with 129 wl) ol 1.01} smweon bog bhydreiite
EE Cla 8 othaved Thu solullon wan f11teved
Thee } through a ©.2%2 meron {filler conan brat ads La ade LT vagy to 18 wm). Filherad Lhroagh oo Awlodn
Can ch Centrlilo OF-26 wembrans. and Tvophtiland to aE 16 yield the Adams bom A azido-3°-
Sen ET . Ca
Cdmt nL daoxyiLhymidins- Bb -nonophosphate a8 4 solid, ite JERS Co CL
Hera GM ’ ;
ARE CE Thig gomponnd was characterized as a nue lsoglda wide ESE 6 ~menophosphale by thes Cnbittis of
Sorat Lee BEE
CRE Do 6 pnubleovidase Lo degrade It to Lhe nua leonide.
LER CL Cl
CLE Ee Ci -
Cote Ce 26 RKxamelo lbs Goosen Dc lrivherrhatseid] © : i wo Yo Jacky bbhymiding ahd:-3 Aside bl dlohon bo bunds :
Sper tr ve dT wl Coe i Si To a 2 - LE : . re co deexythimnidine a.
SRL Eo 3 1, . = :
S5 : JE i . _ nT : eH “i SO :
Fe con wR .
SE a 49 = -
CERN E Co aE rT fo 3. . .
CELE :
Cpr ray | : :
CoE Tir ;
CT RE Ll
Coa ne BAD ORIGINAL
CERT eh Ce Co
Sey pe A [SA . Bop : . 3
Cae
BACH
SERIES CT Ti Te Ee Te a AR ea es RELL
HN Een SL RRR bn ET en adn a Lig iE
SE aR Tee en TT AS RE DEANE
EEE To ELE Loe Coe Thi : v3 EA: 08 © oN Te Ee SR Ce Mae CRE) Ee
PERE Senet : ; Ee LEE aT Ee
SEE eT RL gn CRRA =o SE IN . Lo TR . ToT
Co (a) Bla.(tel-bukylamvonivm)pyrophoesphinta : ‘A column of DOW BB ("Dawex’ isn axchange resin- DOW Chemlasl GLsbhoratories) puridiniom
Co resin was prepared by pouring 49 mt of rosin . fete b into a 26 om dismeber aoluma snd waphed with : i : rater until Ke nore aolanr ented,
Lo Pyroplioaphs be decahvdrata (1.12 ag. 7 v1 mM) wan eee dlasotved Tu 20 wl of water wy! applind ba Lhe
TNC
Lo es luamn The column was alatad with pater, © A :
ST SARE : .
ET 19 128° wml frachion of Lhe alnant uhinh contained hn , : Ch E
Lo UY. shsoxbing wmaterlal was collected The
Coe volumes wan raduasd bo 10 milly vacuosnd tird-n-
Sr Ski 4 . : iB Soe mo : bufylamins (1.2 ml) wae added. Pha vorlima wap roaducadin. vagun and Lhe ragidne wan deiad by
RE 15 aaavaporatiton alth pyridine fan Limen., © The : dle CT product was ntored in a freene (~B°0
Ca NY ii b 5 nT (Lb) Wydrogea form of 37-4aide-b monovhoiphake-
So a=decxy bhymidie Lo :
Cr k The: ‘hydrogen form of the monophosphate was Co
EL Ck Pon Lo for .. 20 prepared by passing the ammonium malt. obtained
EE - . ol © } - >
RT Ca pd, \
Te B A Cem } cn - ha -
CL
SL,
CEL ml - BAD ORIGINAL
Re Lo SE - bes
’
Fo Ee hE P CE ag hae - : - Ca Co no . To Ce ad Rm Bs wl EE eh ce - * : In Bxample 14 (A.1 g. 4.283 mMal) disanlved In
N 8 mh of umtar, Lhrough a 1.6 mh (12 eg ) column
Co of NOW 63 H'. to) Fhosphoromorphalidate Derivative of | 3- oo E._. Anids-3 -deoxythymidine - In 89 ml of water was dimgolved @.283 mMal of the hydrogen form of the monophosphate obtained
Co \_ in. stags b}. HMorpholine (98 ul, 1,13 mMal, 4
B Co. eq.) was added and the solution heated to Co 18 reflux. Dicyslohexyl carbodiimide (0.234. g, i 1.13 mMal, 4 eq.) diseolved in t-butanol (6 ml) 5 ni was, added over a three hour. period. . The 3
EE . Co raaotion wag refluxed overnight. The reaction ~ | wae cooled to room temparature, filtered, and
I 1b the solvents. remaved Jn. _xacug. H®thanol was
NU added and evaporated in. vacuo four timas, The resldue was diesclved 1n methanol and the rhosphoramorphol {date precipl tated hy the ) yoo ‘addition of «ather. Theo precipitate wap
Co 28 trituvated with ether four tiwas snd dried on a : . rotary. evaporator. The title compound wae 1 | obtained. 4 2 \ ar EE
Les BL v - - Bl ~
As = a BAD ORIGINAL Y
Ta . | \
0S se fenlgs se - TOE mo oe
IEE oo phen rr 6 ve sae 2 (d) 1° -Asida-3 -deozythymidine-f -brihesphate tl The phuaphoramerpholidate derivative obtained in atage co), was dried by A removal of pyridine - in__ _vagua four buimes. The bile (n-Bu)gN
Hb pyrophoaphate obtained in stage a) was aleo - dried by removal of pyridine in. _ vYAGDO. Tha
Co ] ; phosphoramorpholidate wae Aineolved in 3 pyridine, F sb, and added to the vessel : — ' containing the pyrophosphate reagent. The bh . 19 reaction wae allowed Lo continne overnight at : ws room temperature. The pyridine une removed 1n
A YAQUQ. Hater was added to ‘the residue and
CL removed in vacuo three times. The residue Was ~ o frozen. . 15 The residue war thawed and dirsolved in 58 nl = of water. The solution was applied to a column
NY (1 x' 10 om) of DFAF Baphadex A-25 which had
CL been equilibrated with = 59 mH ammonium ) o oo blecarhonate. The phosphates were aluted with a
Lo oo 20 300 ml kipear gradient of b@-8aaA mH ammonium : - Co bicarbonate. The fractions containing the oo . diphosphate nucleotide were pcoled as were oe =. | ; Cn -
LL Coe ES BAD ORIGINAL DJ
4 a . gq
Te
Co. RE ; thease containing the treiphnephate mnlantide. oo The pooled diphosphate and triphos hate : a fractions were each dried in vacuo. redissolved oo in water, dried ngain, redimeclved in water and : 6H Lyophilized.
Example 18: Enzymatic Synthesls of 3 -Azlda=p’- : . triphospha ted -deoxvthyeldine . NE : 3 The ©'-triphosphate wag aynthemized from the . 4 . 5‘ -diphorphate nging pyruvate kKinnge and - i 19 nucleoside diphosphate kinase. The reaction
BB mixture contained: 6mM 8 -amida TDP. 12. wi adenas ine triphorphate, AA mH HaCl,, 49 mH : potassium J toarantna-N, Ii ~binl2-athunaan phonic ! aotd) PIPES buffer (pil 8.8), 6 mM
NN 1b phosphenclpyravate, 4 10/m} maleoside ‘diphosphate kinase and 194 Ti/ml pyruvate ; kinase in a final volume of 6 ml. Tha reaction oy © mixture wan incubated at 37°C for 6 daya. The
Cl | ‘reaction mixture was applied to a column {2.5 x ) Ra ~ 20 1 om) of DEAR Sephadex A-Z6 which had been
Si equilibrated with ammoninm hicarbonate, The
RE Lo ; . oo 5 | ~ B3 -
Co B oo . aD ORIGINAL J)
CEReEAT oo ar oo CL ed > fe : ; 3 : h i : . - el | Le EAE : 3 ane oo = siakd . - nucleotides wera alnted with a gradient of {ow ~ 1000 md ammoniom hicarbonate. Fractions containing tha triphosphate were pooled, and
Ce : avéporated to dryneas in _vanuo. The <ompouund 3 b was further purified using » preparative HPLC : i . column (Whatman, Ine., Hagnum 9 8AK)Y eluted }
Lor : with a gradient of 18 - 1 mM potaasiom o | “phosphate, pH 3.6. The resnlting compound wae
Ww. , further purified uweing » DEAE Sephadex A-26
SEE 19 column as above. The fractions containing the pE tetraamhoninm 3" -azido-3" -dsoxythymidine-6"~ he - DE triphosphate were pooled, dried in _ vacua, b Sree memes - FA 1 8B 0 1 VA in water and lyophilised to yield oki the title componnd
Fat : oo oo ’ me : i : 16 Example L7: Antiviral Activity Lo ; ce : (a) (1) Betrovirua - Ioduged Malignanoy
SER - 3" -Anido-3°-deoxythymidine was administered oo
RS to female BALB/c mice Infected with 1.6xint
SE Pfn of the RYB3 strain of Rauscher Murine
Cha oo 20 Leukaemia Virus. Treatment wns nlarbed 4 : i [.:. hours after infection at dosnges of 89 =
CY Co De a bo 3h - BA - wl 5 ‘4 T BAU UesiailvAL 9
Cn " He ah } or } Ce ’ ‘ | vs re -
Geme s .. Ca Ee : 0 Sees ce ERIE to Lo LE
Coa pn Eads . = CTT eee
FET Lie Co le st owl vf 3 tl Ee
RAR © mg/kg intrapariteonaenlly avery 8 hours or . LL a 9.6 or 1.8 mg/ml orally in drinking water.
She Suoh treatmant wap found to prevent ’
Se : : vo oo . infection of apleen calls and subsequent oR iy H . davelopment of eplenowegaly and also
Cb auppressed viraemin. : : (11) HILY-I : : . : Ww. | .
Ch © TM-11 cells (T-cell clone susceptible to oo iE ) | « HTLV@I infection) were co-cultivated with
BT 18 7. irradiated, HTLV-1 producer MJ-tumour cells
TU as follows: dh Ta) TM-11 cells only; oo oo _
Ee 4 : Sa :
AEE oo #2 Db) TH-11 cells end WJ-tumour cells
Cake Co Sl : | -
Sar LE “Xs e) TH-11 cells, MJ-tumour cells and 3° mal Lo Ct Co : :
Th oo 16 “ azido-3 -deoxythymidine (3uM); . BE
EOI Cd) TH-11 cells, MJ-tumour celle and = 3'- he wr azido-3°-deoxythymidine (BuM): oo } : tl , , . .
So a ...e) TH-11 cells, HJ-tumour celle and 3°-
ES EY PE co ood azido-3 -deoxythymidine (27um). : . cd
GoFm CL . EE | “ : pF i ~ \ nL K . : >
Ly Lr . on ] - - BH - 2
LE TL : : ~
SLRs ET hig AE i
CERN - BAD ORIGINAL ¢ ; LE : “ Va } # i i :
E ff a
Ei i ; k. | Dnoday 18, total PHA Wak extracted from esch i : a culture apd dlgeasted with Bam H1 to generate gm 4 Fragment, of the HTLV fonone, independant, of
E any host Flanking sequence and having A i 5 standard wolecnlsre welght. of 3.3 kn. The: ? digest was then probed with radico-labelled 4 Tanbidha [Hr-o vA Shandard probe recognized the 4 Baw HI fragusnt of HTLV : No hybridisation Was ohaarye) for BH), : 143 indicating & tack of virng in the min feched control. A strong Blgnal wee peep for b), the ntreatedn infected central. A yesk slgnal was aheervad with er), Tnaicat ing incomplete : eradication of the virue, snd po hybridisation
Wan noted in od) roe) Indicating com plete
Sateradnat ion of the viru.
Each cid ture Wag alsa probed wil A probes fap
Tell Veceptor B ohain, with x strong signal being generated For a11 Girl bre | showing the 24d contiinoed pregomoe of TH-11 Foy the duration of
Lhe per inen to. : - he ig 8 i a. Fr . i
TA i
Ny P Po ti 3 E 3 p
TH Ek i 3 . bh phi: pi I
A } i . l 3 !
I. i
Bi: ' } a
A ; (by AIDY
PE : +34 K l 3 4 - re (1) Heverse Transcriptase Antlvity
K ; . . or i
G : 3 -Azide-b -triphosphate-3 ~deoxythymidine i -
E | was tested in. yliro against ALDVY : 1 5 transoriptase (ATDY RT). : . 3 V + y ATV RT was purified from pellated and 2 i extracted AIDV by elution through DEAE and 1 phosphonel lulose caolamns., The enzyme . - sotivity was linear through 66) minutes and 12 stable for at least 2 months when stored in fon glvoerol and omg bovine serum albumin ; per mal. Using rA-odT yo 18) ans rhe 1 template primer, ATV RT had a pi opt imnm
Of Tov ta 1.3, a MnCl, optimus © f @.3 wd 1h did on Hatha opt foam of 5 mM. The act iviny in the presesnoe of 6 mt Mal. wan te fold vreater than Lhe motivity in the presence ; SF vod mil Mola Musimal enzymes wsotlv ity ane alas found in Gey to 148 wh KO and tH) “i feo 10 wi Hall, jncorporation of [PH] dTTP
VEE Piiear with respaent [I crf E Ye ] SET i vont nl rat bon, When bepshed, 3 -azido-5 triphosphate-3 deoxythviddine wag Found to bee 5 Competitive inhibitor o fr AIDV RT, ; giving un Ki of @.349 ub when vaing rA-od| 14 15, an the templale-priver. The: wasyme had 4 Km for ATTR oF 4, 81aH, ahiggeating that
A aslde-5 -triphosphate-3 deoxy thymidine binds tigher fo the ansyme than Aven dATTE,
Further expercibsnts with the KT as of avian 1d myeotobhlaataosis CR ERIEN Moloney mil ise bankemdis virus aid ADV, showed 4 azido-
H triphosphate 50 ~decuythyvinidine to Le a terminator of DHA chain elongation, : . J (11) lin. Yitro Anti-AIDV Activity 4 Aldi 3 deny thymidine Was treated and i found to pogseas activity in a nawnber of jpn ’ vitro saa Svs bans, Price af feet FIs Te '
Cl mensurad hy Ansaving rovepae transcriptase . {73 aoldeity dn the superna Lim From
SE inland, Uninet, Ail pay ores rated ctl ls 3 Amide 3 cdeonvihiving die ,
HE
( -
BAD ORIGINAL iv ]
He ; : "i CL Lo affactivaly blocked Lhe Infection hv AIDVof —~ | the HI nnd 1237 hmman lymphoblastoid call 4 liner nt concentrations from 2.7 to a.o313
Ca mor /ml. Similarly, infechion of normal FHA ay b atimylsted white blood cells and cultured hi peripheral blood lympbocyber wan inhibited at drug couvcentratlope as low as 3.413
So mg/ml. Dmg sddition and enbtrachien
Ci WW. experiments in W9 calls revealad that 37- oe 1 pzldn-3" ~deoxythymidine was mont affective
Si when preaent, at, tha Lime of viura co infection of suacephibia cells, bunt still :
Sh oo retained most of itn antiviral ant ivity iy aven whan addad ap lata aes 2A home after a .
Cp 16 initin] AIDV infection. [ohibition of
LE viral replication uns also evident when the
A k drug wee present in the media only during fo ~ the 20 hour period of viruve aneorption. a RLfecta ware aaen At @.13 and $.413 mog/ml.
A 20 3° -Azido-3°-deoxythymidine exbibited no
CE direct anti-RT activity against purified
Se AIDV virions. gimilarly, the drug had i 11ttle or no affect on the production and
Cu | BAD ORIGINAL PN pu i; k - - bas F
A
A
Fi i 3 i
N
; release of wvirvrous from the chronically 4 infected HY AIDV cell line. i ; 1 (111y Froveoting Infection by AIRY } The sbility of 3 -mzide-3 -deoxythymnidine to block infection of cells by AIDV was ! determined as follows. . : ¥ Cloned T4 positive Lets specific T ’ be: lper lymphoovtas were infected with a fro of ATDY lpalates [at challenge doses 14 of up to BEY virions /oell and cell survival after infection was monitored.
After 14d dave 1a culture 10 viral : ovtopathic affects were seen in infected T cells Treated with 8.08 and 1.3 meg/ml 37 - agido- 3d -deosythymidinsg, while antreated, infected cells were H-fold decressed. Cell survival was sleo evaluated in an HTLY-1
Ly ans Format, ATHY snperintected cell linea derived From Lhe cells sbave. A -azido-30 iA deoxythymi tine ab concentrations of 2.7, 2 and A013 aicg/ml totally blockead ~B# .
aytopathet io af feos at 7 dave. Pymtective effants gare geen in Infootionn Induced hy beth cell free virions snd call pepociated virue. 3. Amtede-3 cdecrythvmidine at 3.27
H meg /ml concentration alao af fertively prevenlarl Autopathic ffact indnetion by A laps ralatad Haltian igolate of ATDY. ; Example 18: Tosiolty Arsay
A —antdo-3 dengythymidine uoa admintcterad Lo 18 both mies snd rate. The Lbgg value une in ences of T6500 mg/kg in berth rperien,
Claims (3)
- oo ZL } ! ? . Claims: ! 69 9 4!. A method for the traatment or prophelakie of Aan WTLV-T Anfection in a hnmon which comprisae sdministrating = tharapantinally b affective amount of A cantdo- 3 deaxvthemid ine
- 2. A mathod for the treatment of an WTLV-] Positive lankaemia or lymphoma in a haiman which - comprinras adminietrating a thavapantically “© etfective amount nf 3 caride 3 -denrvthymidina 19 in a therapeutically effective amonnt
- 3. A mathod for the treatmant or prophylaxis , | of an HTLV-1 infeaticn In a human which - comprises admintiataring a therapentically affentivae amon of a pharmaceutical ~ 16 formulation containing ar act fue Ingrediant, : 3 -aaldo-3 ~deovvthvmid ina / - 62 - r BAD ORIGINAL 9 L
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB858506869A GB8506869D0 (en) | 1985-03-16 | 1985-03-16 | Antiviral compound |
GB858511774A GB8511774D0 (en) | 1985-05-09 | 1985-05-09 | Antiviral compounds |
GB858523881A GB8523881D0 (en) | 1985-09-27 | 1985-09-27 | Antiviral compounds |
GB868603450A GB8603450D0 (en) | 1986-02-12 | 1986-02-12 | Antiviral compounds |
PH3353286 | 1986-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PH26994A true PH26994A (en) | 1993-02-01 |
Family
ID=27516578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH35500A PH26994A (en) | 1985-03-16 | 1987-07-06 | Antiviral nucleosides |
Country Status (1)
Country | Link |
---|---|
PH (1) | PH26994A (en) |
-
1987
- 1987-07-06 PH PH35500A patent/PH26994A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4861759A (en) | Antiviral compositions and methods | |
FI85978B (en) | FOERFARANDE FOER FRAMSTAELLNING AV ETT TERAPEUTISKT ANVAENDBART SALT ELLER ESTER AV 3'-AZIDO-3'DEOXITYMIDIN. | |
CA2090024C (en) | Phospholipid derivatives of nucleosides, their preparation, as well as their use as anti-viral medicaments | |
HUE035408T2 (en) | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | |
US20140212382A1 (en) | Purine monophosphate prodrugs for treatment of viral infections | |
US20040063651A1 (en) | Remedies for hepatitis c | |
EP0482081B1 (en) | Antiviral composition | |
US5616566A (en) | Method of inhibiting HIV replication with 2',3'-dideoxyadenosine | |
JPS63310819A (en) | Antiretroviral sugar protein treatment inhibitor | |
EP0216511B1 (en) | Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxycytidine | |
US3624215A (en) | 8-substituted theophyllines as anti-anxiety agents | |
PH26994A (en) | Antiviral nucleosides | |
EP0302263B1 (en) | Therapeutic composition for combatting aids | |
CA2227688C (en) | Methods and compositions for inhibition of viral replication | |
JP2688057B2 (en) | Anti-adenocarcinoma | |
EP0311108A2 (en) | Anti-HIV active 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside | |
JPS61257925A (en) | Antiviral nucleoside | |
CA2279214A1 (en) | Antiviral agents | |
AU712071B2 (en) | Anti-HIV composition containing imidazole derivatives | |
CA1303032C (en) | Antiviral nucleosides | |
CA2025663A1 (en) | Indole derivatives | |
GB2123288A (en) | Anti-thrombotic agent | |
JPH0283325A (en) | Antiviral agent | |
HU220611B1 (en) | Phospholipid derivatives of nucleosides, pharmaceutical compositions comprising same as active ingredient and process for producing them | |
JPS60215626A (en) | Antiviral agent |